
Sign up to save your podcasts
Or


C16 Biosciences wants to replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. But CEO Shara Ticku faces a tough decision in bringing the product to market. Should she start small, with the lower volume personal care market? Or should she dive right into the booming lab-grown food market, with an interested investor? Harvard Business School Senior Lecturer Jeff Bussgang discusses his case, “C16 Biosciences: Lab-Grown Palm Oil.”
By HBR Presents / Brian Kenny4.5
190190 ratings
C16 Biosciences wants to replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. But CEO Shara Ticku faces a tough decision in bringing the product to market. Should she start small, with the lower volume personal care market? Or should she dive right into the booming lab-grown food market, with an interested investor? Harvard Business School Senior Lecturer Jeff Bussgang discusses his case, “C16 Biosciences: Lab-Grown Palm Oil.”

386 Listeners

1,470 Listeners

105 Listeners

154 Listeners

1,099 Listeners

3,992 Listeners

1,379 Listeners

742 Listeners

107 Listeners

176 Listeners

42 Listeners

828 Listeners

678 Listeners

221 Listeners

79 Listeners

170 Listeners

82 Listeners